Pediatrix Medical Group, Inc. (NYSE:MD) Shares Bought by American Century Companies Inc.

American Century Companies Inc. grew its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 13.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 124,395 shares of the company’s stock after purchasing an additional 15,023 shares during the period. American Century Companies Inc. owned approximately 0.15% of Pediatrix Medical Group worth $939,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. raised its holdings in Pediatrix Medical Group by 1.6% during the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after purchasing an additional 164,333 shares in the last quarter. Boston Partners raised its position in Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after acquiring an additional 453,254 shares in the last quarter. Aristides Capital LLC acquired a new stake in Pediatrix Medical Group in the 4th quarter valued at about $246,000. ClariVest Asset Management LLC bought a new position in shares of Pediatrix Medical Group during the 2nd quarter valued at about $1,721,000. Finally, Tidal Investments LLC acquired a new position in shares of Pediatrix Medical Group in the 1st quarter worth approximately $442,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

MD has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price objective for the company in a research note on Friday, June 7th. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. UBS Group increased their price target on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and upped their price objective for the company from $8.00 to $14.00 in a research note on Thursday, September 26th. Finally, Truist Financial lifted their target price on shares of Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Pediatrix Medical Group has a consensus rating of “Hold” and an average target price of $10.30.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the transaction, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James D. Swift sold 11,100 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The disclosure for this sale can be found here. Insiders have sold a total of 68,100 shares of company stock worth $701,889 in the last 90 days. Corporate insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Price Performance

Shares of MD opened at $12.00 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.87. The stock has a market cap of $1.01 billion, a P/E ratio of -14.12, a price-to-earnings-growth ratio of 1.64 and a beta of 1.56. The stock’s 50-day moving average price is $10.12 and its two-hundred day moving average price is $8.90. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $13.01.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.03. The company had revenue of $504.30 million during the quarter, compared to analysts’ expectations of $505.49 million. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.37 earnings per share. On average, equities analysts predict that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.